Quality statement 6: Statins for secondary prevention
Adults with newly diagnosed cardiovascular disease (CVD) are offered atorvastatin 80 mg.
High‑intensity statins are the most clinically effective option for the secondary prevention of CVD – that is, reducing the risk of future CVD events in people who have already had a CVD event, such as a heart attack or stroke. Evidence shows that atorvastatin 80 mg is the most cost‑effective high‑intensity statin for the secondary prevention of CVD, which can improve clinical outcomes.
Evidence of local arrangements to ensure that adults with newly diagnosed CVD are offered atorvastatin 80 mg.
Data source: Local data collection.
Service providers (primary care and secondary care) ensure that adults with newly diagnosed CVD are offered atorvastatin 80 mg.
Healthcare professionals offer atorvastatin 80 mg to adults with newly diagnosed CVD.
Commissioners (NHS England area teams and clinical commissioning groups) ensure that adults with newly diagnosed CVD are offered atorvastatin 80 mg. Commissioners may do this by seeking evidence of practice through clinical audits.
Adults who have been newly diagnosed with CVD are offered a statin called atorvastatin to help reduce their chances of further problems, such as a heart attack or stroke.
Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE guideline CG181 (2014), recommendation 1.3.20
At the time of publication (September 2015) atorvastatin did not have a UK marketing authorisation for secondary prevention of CVD. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's good practice in prescribing and managing medicines and devices for further information.